Check out the latest in aging advances, research, and events from NIA:
- NIA statement on CMS Medicare coverage policy for approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s — Read a statement from NIA Director Richard J. Hodes, M.D.
- Blocking hormone improves Alzheimer’s symptoms in mice — An NIA-supported study found that a hormone can act on neurons in the brain and increase the production of proteins implicated in Alzheimer’s disease, however blocking these receptors decreased Alzheimer’s symptoms in mice.
- Direct link shown between brain inflammation, neuron death, and cognitive changes in mice — A team lead by NIA researchers tested two drugs and found reduced brain inflammation and improvement in memory and attention in mice.
- Three studies assess Medicare Advantage quality incentives and spending — Recent studies, funded in part by NIA, show that Medicare Advantage reduces hospital stays and health care spending, but the quality bonus program did not improve plan quality or enrollment and created a racial disparity in the distribution of Medicare funds.
- Return to expected rates of ambulatory care services after COVID-19 differ by insurance coverage, study finds — As the COVID-19 pandemic progressed through early 2021, the return to expected rates for ambulatory care services was significantly lower among patients with Medicaid or Medicare-Medicaid dual eligibility.
- TREM2 protein seems to protect brain cells from toxic TDP-43 protein — A mouse study shows that the TREM2 protein may help protect the brain from TDP-43-related neurodegeneration.
